Introduction
Stroke is the most lethal and second most incident disease, together with cancer and cardiovascular disease. 1, 2 Ischemic stroke (IS) and intracerebral hemorrhage account for about 85% and 15%, respectively, of all stroke events. 3 The main pathological manifestation of IS is temporary brain tissue ischemia. 1 Ischemia results in reduced neuron number and interrupted neural axon network, and formation of a defected environment around the ischemic region, which prohibits brain self-healing, eventually resulting in the permanent loss of nerve tissue or disabled brain function.
Stem cell therapy, using hematopoietic stem cells (HSCs), 8, 9 neural stem cells (NSCs), 10, 11 endothelial progenitor cells (EPCs) 12 and other types of stem cells, 13, 14 was considered a promising treatment for IS as it may reduce injury and promote rehabilitation after stroke. Mesenchymal stem cells (MSCs) are derived from mesoderm and have the capacity of regeneration and differentiation. MSCs can differentiate into various lineages such as NSCs, which can further differentiate into neurons, astrocytes, oligodendrocytes and so on, 4, 15, 16 with low immunogenicity and high histocompatibility. 1, 15 Compared with other types of stem cells, such as NSCs, EPCs and HSCs, MSCs are more accessible as they can be easily obtained from umbilical cord, bone marrow, fat and other tissues, and can proliferate rapidly in vitro with little ethical constraints. 15 Preliminary preclinical studies using MSCs to treat IS have shown beneficial effects. [17] [18] [19] In animal models, researchers found the transplanted cells migrated to lesions, secreted neurotrophic factors, remitted inflammatory response and promoted plasticity and revascularization thereby minimizing the damage. [18] [19] [20] Although both preclinical studies and studies with experimental models regarding MSC transplantation therapies for IS have been carried out, [17] [18] [19] the clinical application of MSCs still has a long way to go due to its unverified safety and therapeutic effects. To address this issue, we conducted a meta-analysis of published clinical trials treating IS with MSCs, to provide scientific references for upcoming research and future clinical application.
Materials and methods search strategy and selection criteria
Studies were identified from PubMed, Web of Science, Cochrane Library, Embase, Wanfang and CNKI database, with key terms ("mesenchymal stem cells" or "MSC") and ("ischemic stroke" or "cerebral infarction" or "cerebral ischemia" or "brain ischemia"), without language restriction. The last search was performed in October 2017.
Studies were included if they fulfilled the following inclusion criteria: case-controlled trials involving IS patients; participants were diagnosed with IS and without malignant tumor, pregnancy and lactation; and patients in the experimental group received both MSC transplantation and IS routine treatment (RT; including conventional medical therapy and rehabilitation training treatment) combined therapy, and those in control group were treated by RT alone.
Data extraction and quality assessment
All data collection and extraction were performed by two authors (PX and MW) independently. The following information was summarized: author's names, years of publication, locations, type of IS, samples sizes, patients' ages, study parameter types, therapeutic regimens, administration routes, MSC dosages and adverse events during the MSC therapy. Trials' quality was assessed for risk of bias following the instruction of Cochrane Handbook. 21 
Outcome definition
Treatment efficacy was assessed in terms of National Institutes of Health Stroke Scale (NIHSS), Barthel index (BI), Fugl-Meyer Assessment (FMA) and Functional Independence Measure (FIM). The frequencies of adverse events were gathered and assessed for MSC therapy safety.
statistical analysis
This meta-analysis was performed using Review Manager 5.3 (Cochrane Collaboration). The therapeutic efficacy was evaluated by odds ratio (OR) and presented with 95% CI. P,0.05 indicates differences with statistical significance. The appropriate analysis model was determined by analyzing the heterogeneity between trials by Cochran's Q test. 22 Studies with I 2 ,50% or P.0.1 were considered homogenous.
Publication bias was evaluated based on funnel plots. Sensitivity analysis on subgroups was also performed to assess the impact of MSC types, cell administration methods and patients' characteristics on clinical outcomes.
Results

search results
A total of 2,998 articles were initially identified, and 2,921 were excluded for lacking clinical trials (n=2,693), duplication and repetition (n=177) or being unrelated (n=51). The later detailed assessment further excluded 18 articles with insufficient data, 23 reviews or case reports or meta-analyses and 13 articles without control group. A total of 23 trials with 1,279 IS patients were finally identified meeting the restrict inclusion criteria of this research (Figure 1 ).
study and patient characteristics
After selection, all included trials were found to have been conducted in Asia. Two studies were conducted in Korea, 23, 35 Therapeutics and Clinical Risk Management 2018:14 submit your manuscript | www.dovepress.com
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MsC transplantation for ischemic stroke two in India 24, 25 and the rest of the included studies in China. MSCs were obtained from bone marrow in 18 studies, [23] [24] [25] [26] [27] [28] [29] [30] 32, [35] [36] [37] [40] [41] [42] [43] [44] [45] from umbilical cord in three studies 33, 34, 38 and from umbilical cord blood in two studies. 31, 39 Cells were administered through peripheral vein in 14 studies, 23-27, 30,32,34,35,37,40-43 subarachnoid in five studies, 28, 29, 36, 44, 45 intrathecal in three studies 31, 33, 39 and intracarotid artery in one study. 38 In total, 625 IS patients accepted MSC and RT combined therapy, and 654 patients were treated by RT alone. Detailed information about the involved studies and participants is summarized in Tables 1 and 2 .
Quality assessment
Bias risk of involved trials is shown in Figure 2 . Sixteen studies were determined as low risk, five researches were not truly randomized controlled trials and the other two studies did not have clear illustration of randomization procedures. Seven trials did not provide clear description of allocation and performance concealment. All the included studies were free of detection risk. Three trials missing the follow-up study were considered as high risk, and one study with selective reporting was considered as unclear risk.
Therapeutic efficacy assessments effectiveness of MsCs assessed by the nihss score
The analysis of involved trials showed that after MSC therapy, the NIHSS score was reduced in the first, second, Figure S1 ). As shown in Figure 3 , compared to the control group, the NIHSS score of the experimental group was lower in the first (OR=−1.92, CI=−3.49 to −0.34, P=0.02) and third month (OR=−2.65, CI=−3.40 to −1.90, P,0.00001).
effectiveness of MsCs assessed by the Bi score
The postoperative BI score was increased after combined therapy in the first, second, third and sixth month and after 12 months (1 month: OR=30.14, CI=29. Figure S2 ). In the comparison between patients treated by combined therapy and RT alone, the BI score in the combined therapy group was higher in the first and sixth month (1 month: OR=0.99, CI=0.19-1.79, P=0.02; 6 months: OR=10.10, CI=3.07-17.14, P=0.005; Figure 4 ).
effectiveness of MsCs assessed by the FMa score
The FMA score after combined therapy was significantly increased in the first, second, third and sixth month, and 
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effectiveness of MsCs assessed by the FiM score
As shown in Figure 3 , the FIM score was increased after combined therapy, especially in the first, third and sixth month postoperation (1 Figure S4 ). Meanwhile, the FIM score in the combined therapy group was higher than that of the control group in the first and sixth month (1 month: OR=15.61, CI=−0.02 to 31.24, P=0.05; 6 months: OR=16.56, CI=9.06-24.06, P,0.0001; Figure 6 ).
adverse event assessment
We evaluated the safety of MSC therapy in this metaanalysis. The most common side effects of MSC treatment were headache and fever, which usually subsided within 24 hours without treatment. No serious adverse events were reported in the involved studies (Table 1) . However, the incidence of side effects in experimental and control groups was not compared in most included trials. Three studies 25, 35, 42 conducted the comparison of adverse events including 
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MsC transplantation for ischemic stroke Figure 7 ). 28 Feng et al 31 Bhasin et al 24 Feng et al 31 Hu et al 33 Liu et al 36 Meng et al 37 Chen et al 28 Feng et al 31 Hu et al 33 Liu et al 36 Meng et al 37 Sun et al 41 Cai et al 26 Chen et al 28 Ji et al 34 Meng et al 37 Bhasin et al 25 Bhasin et al 15 and vascular endothelial growth factor, 3, 51 MSCs also promote the differentiation of endogenous neural stem and progenitor cells. Most importantly, the low immunogenicity of MSCs reduces the possibility of graft-versus-host reaction. 1, 15 In recent years, several studies reported that MSC therapy is a safe and feasible treatment option for IS, but different clinical protocols among studies may bring different therapeutic effects. In this study, we performed an extensive and systematic analysis of published clinical trials to assure statistical reliability. Our meta-analysis revealed that compared to IS patients treated by RT alone, those treated by 
Publication bias
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MsC transplantation for ischemic stroke MSC and RT combined therapy exhibited more favorable therapeutic efficacy, indicated by decreased NIHSS and increased BI, FMA and FIM scores.
MSC therapy has been applied to treat refractory diseases for years with satisfied safety record, [52] [53] [54] [55] and our analysis showed that MSCs were safe in treating IS as well. No serious adverse events have been reported during MSC therapy. Most common side effects, including fever and headache, usually resolved naturally. However, relevant studies were insufficient, and the potential long-term toxicity and the risk of tumor formation are unknown, which usually take years to occur. More research evidence will be required to support the safety of combined therapy.
Therapeutic effects of MSC therapy may be affected by infusion routes, cell dosages, cell types and patients' characteristics. We found that intravenous infusion is generally superior to subarachnoid injection in therapeutic effects, but there were also contradicted conclusions drawn from different researches. There are articles that claimed that local subarachnoid injection may deliver a larger number of transplanted MSCs to the stroke lesion thereby promoting nerve recovery and regeneration. 2, 56 However, the different routes of cell infusion did not make big difference in other researches, 57 which speculated that MSCs treat IS through releasing growth factors and antiapoptotic factors instead of homing to the nerve system. 3, 58 The treatment effect varies at different time points of detection, and dosages of transfused MSCs are a key factor in therapeutic strategy optimization. There are studies that showed that increased number of infused cells contributed to favorable clinical efficacy, 57 but currently published literature is still not sufficient to perform reliable statistical analysis. Sources of MSC may also associate with treatment outcomes. Based on our extracted data, autogenous MSCs were associated with increased BI and FIM score, indicating a better therapeutic effect than allogenic MSCs for IS. However, our data were not sufficient, and more research evidence is needed to support this conclusion. The optimal conduction time of cell delivery is also undetermined 
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Tsang et al 42 Lee et al 35 Bhasin et al 25 Lee et al 35 Bhasin et al 25 Lee et al 35 Bhasin et al 25 Lee et al yet. Preclinical studies showed that early intervention leads to an obvious relief of neurological defects. 2, 59 Our subgroup analysis suggested no significant difference in outcomes between the acute and chronic phases of stroke.
Limitations
There are some limitations in this analysis. First of all, the numbers of involved studies and patients were small and the follow-up period was short, which may cause publication bias. Second, all trials included in this paper were mainly conducted in Asian countries. There were indeed several trials conducted in non-Asian countries included upon the first retrieve. However, no paper meeting our inclusion criteria has been produced based on these trials, and studies were excluded due to insufficient data, and being case reports, unrelated to MSC therapy or without control group. We will keep paying close attention to global studies in this field and carry out further analyses in our later studies. Third, our data were partly extracted from published papers rather than original patient records, which means we were not able to avoid the analytical bias based on the information presented in them. In addition, different trials evaluated the treatment efficacy by different outcomes, which have to be summarized using various scales when assessed in this study, leading to small sample sizes in each statistical analysis. Due to above limitations, future studies and generated data will be valuable to further verify the safety and efficacy of MSC therapy.
Conclusion
In summary, our analysis verified the safety and efficacy of MSC therapy for IS. It significantly mitigated neurological defects and improved life quality of IS patients, without causing serious adverse events. Therefore, MSC therapy is a promising treatment option for IS patients.
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